1H NMR-based dynamic metabolomics delineates the therapeutic effects of Baoyuan decoction on isoproterenol-induced cardiac hypertrophy

被引:18
作者
Du, Zhiyong [1 ]
Wen, Ran [1 ]
Liu, Qian [1 ]
Wang, Jinlong [1 ]
Lu, Yingyuan [1 ]
Zhao, Mingbo [1 ]
Guo, Xiaoyu [1 ]
Tu, Pengfei [1 ]
Jiang, Yong [1 ]
机构
[1] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
关键词
Cardiac hypertrophy; Heart failure; Dynamic metabolomics; H-1; NMR; Baoyuan decoction; OXIDATIVE STRESS; HEART-FAILURE; INFLAMMATION; METABOLITES; DYSFUNCTION; BIOMARKERS; PATHWAYS;
D O I
10.1016/j.jpba.2018.09.049
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Cardiac hypertrophy (CH) is a major risk factor for many serious heart diseases. Sustained CH is catastrophic, resulting in cardiac dysfunction that eventually leads to heart failure (HF). Baoyuan decoction (BYD) is a famous traditional Chinese medicine (TCM) formula for supplementing and reinforcing Qi, clinically used for the treatment of cardiovascular diseases (CVDs). However, the therapeutic effects of BYD on CH remain unidentified. We herein investigated the effect of BYD on isoproterenol (ISO)-induced CH in rats and the underlying mechanisms by comprehensive pharmacodynamics and H-1 NMR-based dynamic metabolomics analysis of the plasma and urine samples. Results showed that BYD treatment markedly attenuated ISO-induced CH as evidenced by decreasing the left ventricular wall thickness, pathological cardiomyocyte hypertrophy, myocardial collagen fiber deposition and apoptosis, and plasma natriuretic peptide levels. Multivariate trajectory analysis revealed that the BYD treatment could restore the CH disturbed plasma and urinary metabolite profiles towards the normal metabolic status featuring with a time-dependent tendency. Moreover, the key metabolic alterations in CH rats at different BYD-treated time stages involved energy metabolism, oxidative stress responses, amino acid metabolism, and gut microbiota metabolism. Of particularly, the significant roles of BYD for treating CH lie in the improvement of cardiac energy generation and antioxidant capacity. Our investigation provides a holistic view of BYD for therapeutic intervention of CH through monitoring of the dynamic metabolic changes and the results indicate that BYD may be applied as a potential agent for treating CH. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:64 / 77
页数:14
相关论文
共 30 条
  • [1] Complex Energy Metabolic Changes in Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction
    De Jong, Kirstie A.
    Lopaschuk, Gary D.
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2017, 33 (07) : 860 - 871
  • [2] Integration of Metabonomics and Transcriptomics Reveals the Therapeutic Effects and Mechanisms of Baoyuan Decoction for Myocardial Ischemia
    Du, Zhiyong
    Shu, Zeliu
    Lei, Wei
    Li, Chun
    Zeng, Kewu
    Guo, Xiaoyu
    Zhao, Mingbo
    Tu, Pengfei
    Jiang, Yong
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [3] 1H-NMR-Based Metabolic Analysis of Human Serum Reveals Novel Markers of Myocardial Energy Expenditure in Heart Failure Patients
    Du, Zhiyong
    Shen, Anna
    Huang, Yuli
    Su, Liang
    Lai, Wenyan
    Wang, Peng
    Xie, Zhibing
    Xie, Zhiquan
    Zeng, Qingchun
    Ren, Hao
    Xu, Dingli
    [J]. PLOS ONE, 2014, 9 (02):
  • [4] Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy
    El-Sherbeni, Ahmed A.
    El-Kadi, Ayman O. S.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2014, 87 (03) : 456 - 466
  • [5] Quantitating Metabolites in Protein Precipitated Serum Using NMR Spectroscopy
    Gowda, G. A. Nagana
    Raftery, Daniel
    [J]. ANALYTICAL CHEMISTRY, 2014, 86 (11) : 5433 - 5440
  • [6] Metabolomics and traditional Chinese medicine
    Hu, Chunxiu
    Xu, Guowang
    [J]. TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2014, 61 : 207 - 214
  • [7] Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling
    Hunter W.G.
    Kelly J.P.
    McGarrah R.W., III
    Kraus W.E.
    Shah S.H.
    [J]. Current Heart Failure Reports, 2016, 13 (3) : 119 - 131
  • [8] Metabolomic Analysis in Heart Failure
    Ikegami, Ryutaro
    Shimizu, Ippei
    Yoshida, Yohko
    Minamino, Tohru
    [J]. CIRCULATION JOURNAL, 2018, 82 (01) : 10 - 16
  • [9] Hypoxanthine causes endothelial dysfunction through oxidative stress-induced apoptosis
    Kim, You-Jin
    Ryu, Hye-Myung
    Choi, Ji-Young
    Cho, Jang-Hee
    Kim, Chan-Duck
    Park, Sun-Hee
    Kim, Yong-Lim
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 482 (04) : 821 - 827
  • [10] Energy Metabolic Reprogramming in the Hypertrophied and Early Stage Failing Heart A Multisystems Approach
    Lai, Ling
    Leone, Teresa C.
    Keller, Mark P.
    Martin, Ola J.
    Broman, Aimee T.
    Nigro, Jessica
    Kapoor, Kapil
    Koves, Timothy R.
    Stevens, Robert
    Ilkayeva, Olga R.
    Vega, Rick B.
    Attie, Alan D.
    Muoio, Deborah M.
    Kelly, Daniel P.
    [J]. CIRCULATION-HEART FAILURE, 2014, 7 (06) : 1022 - U287